NeuroSense plans PrimeC new drug filing with Health Canada for ALS

NeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting. * The submission package includes Phase 2b PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220830PR_NEWS_USPR_____LN09247) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

NeuroSense Therapeutics plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS, following a Pre-NDS meeting. The submission includes Phase 2b PARADIGM data demonstrating a 14.9-month median survival benefit (HR 0.35, p=0.0037).

NeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting. * The submission package includes Phase 2b PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220830PR_NEWS_USPR_____LN09247) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)